Greenwich Biosciences Competitors, Revenue, Alternatives and Pricing

Claim your profile

Overview

Location:
Total Funding:N/A
Industry:Pharma
Founded:2013
Lead Investor(s):N/A

Estimated Revenue & Financials

  • Greenwich Biosciences's estimated annual revenue is currently $56.3M per year.
  • Greenwich Biosciences's estimated revenue per employee is $201,000

Employee Data

  • Greenwich Biosciences has 280 Employees.
  • Greenwich Biosciences grew their employee count by 58% last year.
  • Greenwich Biosciences currently has 31 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingOnline ReviewPricing
Advertise Here
Trifecta Clinic...
$15.3M763%N/A-N/A
DURECT Corporat...
N/A125N/AN/A-N/A
Rancho BioScien...
$13.1M6523%N/A-N/A
ApotheCom
$53.1M264N/AN/A-N/A
Tlc Pharmacy
$10.1M504%N/A-N/A
Otsuka America
$13.5M6720%N/A-N/A
endpoint Clinic...
$62.1M30910%N/A-N/A
GCAM
$22.5M1125%N/A-N/A
VistaGen Therap...
N/A17N/AN/A-N/A
ZO Skin Health
$69.5M3462%N/A-N/A
Missing a competitor? Contribute!?
Submit

Greenwich Biosciences' vision is to make a positive difference in the lives of patients through the development of a portfolio of cannabinoid prescription medicines in a wide range of therapeutic indications. Our strategy is to build on our world leading position in the field of cannabinoid science and in the research, development and commercialization of cannabinoid molecules as novel prescription pharmaceutical therapeutic candidates. Epidiolex is Greenwich's lead cannabinoid product candidate and is a proprietary oral solution of pure plant-derived cannabidiol, or CBD. Greenwich's Epidiolex development is initially concentrating on severe, orphan, early-onset, treatment-resistant epilepsy syndromes including Dravet syndrome, Lennox-Gastaut syndrome (LGS), Tuberous Sclerosis Complex (TSC) and Infantile Spasms (IS). We have made a commitment to establish a fully integrated US operation to commercialize the product, with our US headquarters in Carlsbad, CA. Our Parent company (GW Pharmaceuticals, PLC), was founded in 1998 and is based in the UK. We are continuing to build out our team and are looking for talented individuals dedicated to making a difference in the lives of our patients.

keywords:N/A

280

Number of Employees

$56.3M

Revenue (est)

31

Current Jobs

58%

Employee Growth %

N/A

Total Funding

N/A

Valuation

N/A

Accelerator

N/A

Type

Greenwich Biosciences News

09/04/2019 - GW Pharmaceuticals to Present at the Morgan Stanley 17th ...

04, 2019 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc and its U.S. subsidiary Greenwich Biosciences Inc. (NASDAQ: GWPH, GW, the ...

09/05/2019 - Cannabidiol Market insights offered in a recent report

GW Pharmaceutical plc and Greenwich Biosciences, GW's subsidiary announced FDA's approval of EPIDIOLEX® cannabidiol oral solution in ...

08/26/2019 - For GW Pharma CEO Justin Gover, The CBD Trend Started 20 ...

In 2015, Gover relocated to California to open operations in the US. GW's US subsidiary, called Greenwich Biosciences, is in Carlsbad, a city in ...